|This Slide: #21 of 83|
Slide #21. Emergent BioSolutions — Cangene Corporation
Emergent BioSolutions (NYSE:EBS)
Cangene Corporation (CNJ)
Cangene Corporation ("Cangene") (TSX: CNJ) announced that its shareholders have approved the previously announced acquisition by Emergent BioSolutions ("Emergent") (NYSE: EBS) at a special meeting held today. The acquisition will be implemented through a Plan of Arrangement under Canadian law, under which Cangene shareholders will receive US$3.24 per share (C$3.571 per share) in cash, for an aggregate purchase price of US$222 million (approximately C$245 million2).
Emergent BioSolutions is a life sciences company focused on providing a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). Co. is focused on products and solutions that address the following five distinct PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives; emerging infectious diseases; travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). Co. has a product portfolio of ten marketed products (vaccines, therapeutics, and drug-device combination products).
EBS SEC Filing Email Alerts Service
Open the EBS Page at The Online Investor »
Buy (3.14 out of 4)